HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

A 40926

from Actinomadura; active against gram-positive bacteria & Neisseria gonorrhoeae

Also Known As:

A-40926; A40926; MDL 62,476; MDL 62476; MDL-62,476; MDL-62476

Networked: 8 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycopeptides: 1928
    - Lipoglycopeptides: 148
      - Teicoplanin: 1092
        A 40926: 8
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Glycopeptides: 1928
    - Lipoglycopeptides: 148
      - Teicoplanin: 1092
        A 40926: 8

Experts

1.	Bibb, Mervyn: 2 articles (01/2020 - 08/2015)
2.	Binda, Elisa: 2 articles (01/2020 - 11/2014)
3.	Marcone, Giorgia Letizia: 2 articles (01/2020 - 11/2014)
4.	Marinelli, Flavia: 2 articles (01/2020 - 11/2014)
5.	Andreo-Vidal, Andres: 1 article (01/2020)
6.	Yushchuk, Oleksandr: 1 article (01/2020)
7.	Alduina, Rosa: 1 article (08/2015)
8.	Lo Grasso, Letizia: 1 article (08/2015)
9.	Maffioli, Sonia: 1 article (08/2015)
10.	Puglia, Anna Maria: 1 article (08/2015)

Related Diseases

1.	Infections 08/01/2015 - "A40926 is the precursor of dalbavancin, approved for treatment of skin infections by Gram-positive bacteria. " 11/04/2014 - "Nonomuraea sp. ATCC 39727 is the producer of A40926, which is the natural precursor of the second generation semi-synthetic glycopeptide dalbavancin, very recently approved for acute bacterial skin and skin structure infections. " 02/01/2002 - "Biosearch Italia and Versicor are developing dalbavancin, a novel semisynthetic derivative of the natural glycopeptide A-40926 for the potential treatment of Gram-positive infections. " 01/01/2020 - "Nonomuraea gerenzanensis ATCC 39727 is the most studied representative species since it produces the glycopeptide antibiotic (GPA) A40926 - the precursor of the clinically relevant antibiotic dalbavancin, approved by the FDA in 2014 for the treatment of acute skin infections caused by multi-drug resistant Gram-positive pathogens. "
2.	Sepsis (Septicemia) 09/01/1988 - "In experimental septicemia in the mouse, A40926 A + B complex and its derivatives had activity proportional to their MIC for the test organism."
3.	Gram-Positive Bacterial Infections 08/06/2014 - "Teicoplanin A2-2 (Tei)/A40926 is the last-line antibiotic to treat multidrug-resistant Gram-positive bacterial infections, e.g., methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE). "
4.	Gonorrhea 12/01/1987 - "These properties suggest that A40926 may have potential in the therapy of gonorrhea."
5.	Body Weight (Weight, Body) 02/01/1988 - "We studied the pharmacokinetics of A40926 in rats after single intravenous and subcutaneous 10-mg/kg (body weight) doses. "

Related Drugs and Biologics

1.	dalbavancin
2.	Glycopeptides
3.	Anti-Bacterial Agents (Antibiotics)
4.	Teicoplanin
5.	Vancomycin

Related Therapies and Procedures

1.	Therapeutics